Bioavailable Testosterone: How to Interpret Your Result

What Bioavailable Testosterone Actually Measures

Bioavailable testosterone represents the portion of circulating testosterone that tissues can use. Total testosterone in blood exists in three pools: about 1 to 3% circulates free (unbound), roughly 25 to 50% binds loosely to albumin, and the remaining 50 to 70% binds tightly to sex hormone-binding globulin (SHBG). The SHBG-bound fraction cannot cross cell membranes under normal conditions.

Bioavailable testosterone = free testosterone + albumin-bound testosterone. Because albumin binding is weak (association constant roughly 1,000 times lower than SHBG binding), albumin-bound testosterone dissociates easily in capillary beds and enters target cells. The Endocrine Society's 2018 clinical practice guideline recommends measuring or calculating free or bioavailable testosterone when total testosterone is borderline and SHBG abnormalities are suspected.

This distinction matters clinically. A man with total testosterone of 400 ng/dL but high SHBG of 80 nmol/L may have a bioavailable testosterone well below the reference range. His lab slip says "normal total T." His symptoms say otherwise.

How Bioavailable Testosterone Is Calculated

Most labs do not measure bioavailable testosterone directly. They calculate it. The gold-standard direct method, ammonium sulfate precipitation, is rarely available outside research settings. Instead, clinicians rely on the Vermeulen equation, a validated formula published by Alex Vermeulen and colleagues in 1999. It takes three inputs: total testosterone, SHBG, and albumin concentration (usually assumed at 4.3 g/dL).

The calculation uses mass-action binding equations to determine the free fraction, then adds the albumin-bound component. Several online calculators exist, including the widely used ISSAM calculator based on Vermeulen's original model.

Accuracy depends on accurate SHBG measurement. If your lab uses immunoassay for total testosterone (most do), the result can diverge from liquid chromatography-tandem mass spectrometry (LC-MS/MS), especially at low testosterone concentrations seen in women and hypogonadal men. The Endocrine Society recommends LC-MS/MS as the reference method for testosterone measurement.

Equilibrium dialysis remains the reference standard for free testosterone measurement, but it is expensive and slow. For most clinical decisions, the calculated bioavailable testosterone using Vermeulen's equation provides reliable data when paired with a quality SHBG assay.

Normal Bioavailable Testosterone Ranges by Age and Sex

Reference ranges shift with age, sex, and assay methodology. No single number applies universally.

For adult men aged 20 to 49, bioavailable testosterone typically falls between 131 and 682 ng/dL. After age 50, the lower end drops as SHBG rises approximately 1.2% per year while total testosterone production declines. The Massachusetts Male Aging Study (MMAS), a longitudinal cohort of 1,709 men, documented a cross-sectional decline in bioavailable testosterone of 2 to 3% per year after age 30.

For premenopausal women, bioavailable testosterone ranges roughly from 1.0 to 9.5 ng/dL, though standardized female reference ranges remain poorly established. The 2019 Endocrine Society position statement on testosterone therapy in women noted that no well-accepted female testosterone threshold exists for diagnosing androgen deficiency. Postmenopausal women typically see lower values, but SHBG also drops after menopause, partially offsetting the decline.

Age-stratified ranges from your specific lab should guide interpretation. A 65-year-old man with a bioavailable testosterone of 110 ng/dL might be within the age-adjusted reference interval at some labs but flagged low at others.

What Drives Bioavailable Testosterone Up or Down

SHBG is the primary modifier. Anything that raises SHBG lowers bioavailable testosterone (even if total T stays flat), and anything that lowers SHBG raises it.

Conditions and factors that increase SHBG and thereby reduce bioavailable testosterone include aging, hyperthyroidism, liver cirrhosis, estrogen therapy (including oral contraceptives), anticonvulsants like phenytoin, and low caloric intake. Hepatic SHBG production responds to insulin, thyroid hormone, and estradiol signaling.

Conditions that decrease SHBG (raising bioavailable testosterone relative to total) include obesity, insulin resistance, type 2 diabetes, hypothyroidism, nephrotic syndrome, glucocorticoid use, and androgenic anabolic steroid use. In the EMAS cohort (N=3,369 European men aged 40 to 79), BMI was the strongest independent predictor of low SHBG and low total testosterone, while bioavailable testosterone was relatively preserved in obese men due to suppressed SHBG.

This is why total testosterone alone can mislead. An obese man may show a total testosterone of 280 ng/dL (low), but his SHBG may be 12 nmol/L, and his bioavailable testosterone might sit at the lower end of normal. Conversely, a lean man on thyroid replacement might show a total testosterone of 500 ng/dL (mid-range) while his SHBG of 75 nmol/L drives bioavailable testosterone below the threshold.

How to Interpret a Low Bioavailable Testosterone Result

A low bioavailable testosterone matters only in context. The Endocrine Society defines male hypogonadism as consistently low serum testosterone plus symptoms. Numbers without symptoms do not make a diagnosis.

Symptoms associated with low bioavailable testosterone in men include reduced libido, erectile dysfunction, fatigue, loss of muscle mass, increased body fat, depressed mood, and decreased bone mineral density. In the EMAS study, only three symptoms (poor morning erections, low sexual desire, and erectile dysfunction) showed a syndromic association with low testosterone in men over 40.

If your result comes back low, the next steps are:

1. Confirm with a repeat morning draw. Testosterone has a circadian rhythm peaking between 7 and 10 AM.
2. Check SHBG, LH, FSH, prolactin, and a metabolic panel.
3. Rule out reversible causes: opioid use, glucocorticoids, severe obesity, sleep apnea, and pituitary pathology.
4. Consider imaging (pituitary MRI) if LH/FSH are inappropriately low or prolactin is elevated.

Dr. Shalender Bhasin, who led the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 790 men aged 65 and older, has stated: "The diagnosis of hypogonadism requires the presence of signs and symptoms AND unequivocally and consistently low testosterone concentrations."

For women, low bioavailable testosterone remains controversial as a clinical entity. The Global Consensus Position on testosterone therapy for women concluded that a blood level of testosterone cannot be used to diagnose a "female androgen deficiency syndrome." Symptom assessment and exclusion of other causes should come first.

How to Interpret a High Bioavailable Testosterone Result

High bioavailable testosterone in men is less commonly a clinical problem than low values, but it can signal exogenous androgen use, an androgen-secreting tumor, or congenital adrenal hyperplasia. In men using testosterone replacement therapy (TRT), elevated bioavailable testosterone may indicate overreplacement.

The Endocrine Society TRT guideline recommends targeting mid-normal total testosterone (450 to 600 ng/dL) during replacement and monitoring hematocrit, PSA, and lipids. If bioavailable testosterone rises disproportionately, check whether SHBG has dropped (common with injectable testosterone, which suppresses SHBG more than topical formulations).

In women, elevated bioavailable testosterone can indicate polycystic ovary syndrome (PCOS), ovarian hyperthecosis, Cushing syndrome, or an adrenal/ovarian tumor. The 2023 international evidence-based PCOS guideline recommends calculated free testosterone or bioavailable testosterone as a more sensitive marker for hyperandrogenism than total testosterone, particularly when SHBG is altered by oral contraceptive use.

A single high value requires confirmation. Rule out sample timing errors (afternoon draws yield lower values, so a morning high is more reliable) and assay interference before pursuing an endocrine workup.

How to Raise Low Bioavailable Testosterone

Treatment depends on the cause. If SHBG is driving the deficit, the target may be SHBG reduction rather than testosterone supplementation.

For men with confirmed hypogonadism, testosterone replacement therapy remains first-line. The Endocrine Society recommends treatment when total testosterone is below 300 ng/dL on two morning samples with consistent symptoms. Options include topical gels (testosterone 1% gel, 50 to 100 mg daily), intramuscular injections (testosterone cypionate 100 to 200 mg every 1 to 2 weeks), and subcutaneous pellets.

Lifestyle interventions can improve bioavailable testosterone in men with obesity-associated low T. In the Diabetes Prevention Program (DPP), men who lost 7% of body weight through diet and exercise saw SHBG and total testosterone rise, though bioavailable testosterone changes were modest. Resistance training increases testosterone acutely, though evidence for sustained baseline elevation remains mixed.

Sleep optimization matters. Restricting sleep to 5 hours per night for one week reduced daytime testosterone by 10 to 15% in healthy young men. Addressing obstructive sleep apnea with CPAP has shown variable testosterone recovery depending on BMI.

Clomiphene citrate (25 to 50 mg daily, off-label) can raise endogenous testosterone in younger men who want to preserve fertility. A retrospective series of 86 hypogonadal men showed clomiphene increased total testosterone from 228 to 612 ng/dL over a mean of 19 months. This approach avoids the testicular suppression caused by exogenous testosterone.

How to Lower Elevated Bioavailable Testosterone

Lowering bioavailable testosterone is primarily relevant in women with hyperandrogenism. PCOS management is the most common clinical scenario.

Combined oral contraceptives (COCs) are first-line for premenopausal women with PCOS-related androgen excess. COCs raise SHBG (reducing bioavailable testosterone) and suppress ovarian androgen production. The 2023 PCOS guideline recommends low-dose COCs containing 20 to 35 mcg ethinyl estradiol, preferring formulations with less androgenic progestins.

Spironolactone (50 to 200 mg daily) acts as an androgen receptor blocker and reduces adrenal androgen synthesis. It is often combined with COCs in women who do not respond to COCs alone.

For men, high bioavailable testosterone from TRT overreplacement is managed by dose reduction. If an androgen-secreting tumor is identified, surgical removal is definitive.

Weight loss in obese women with PCOS can lower total testosterone. The 2023 PCOS guideline recommends a 5 to 10% body weight reduction as a first intervention, noting improvements in hyperandrogenism, ovulation, and metabolic markers.

When to Retest and How Often to Monitor

After an initial abnormal result, confirm with a second fasting morning sample drawn at least 2 to 4 weeks later. A single value should never drive treatment initiation.

Once on TRT, the Endocrine Society recommends checking testosterone levels 3 to 6 months after initiation and then annually. For injectable testosterone, draw the trough sample (immediately before the next injection) to assess the nadir. For gels, draw 2 to 8 hours after application.

Monitor these alongside bioavailable testosterone: hematocrit (stop or reduce TRT if hematocrit exceeds 54%), PSA (obtain a baseline before starting TRT, recheck at 3 to 6 months and 12 months), bone mineral density (if osteoporosis was present at baseline, repeat DXA at 1 to 2 years), and lipid panel.

Women on anti-androgen therapy should have repeat testosterone and SHBG measured at 3 to 6 months. Serum potassium monitoring is required with spironolactone due to its potassium-sparing diuretic effect.

A bioavailable testosterone result is a snapshot. It reflects that morning's hormonal state, influenced by sleep, acute illness, medications, and caloric intake in the preceding 24 hours. Trends across multiple measurements carry far more clinical weight than any isolated number.